Robin Feldman on Drug Patents, Generics, and Drug Wars

Episode Summary

Executive Summary: Russ Roberts and Robin Feldman examine how Hatch-Waxman expanded generic drug entry but also created loopholes for branded firms to delay competition. Feldman explains weak patents, pay-for-delay settlements, hidden side deals, product hopping, REMS/sample blockades, and citizen petitions as evolving strategies that preserve monopoly rents and raise prices.

Main Topics: Hatch-Waxman’s original goals and achievements (Priority: 5/5): The 1984 law aimed to speed generic entry by letting generics rely on brand-name safety/efficacy data and by creating a litigation pathway to resolve patents before launch. Weak patents and patent-system overload (Priority: 5/5): Many pharmaceutical patents are difficult to evaluate, often weak, and expensive to challenge; this makes even invalid patents effective barriers to entry. Pay-for-delay settlements (Priority: 5/5): Brand firms paid first-filing generics to stay off the market, exploiting the six-month exclusivity window and delaying broader generic competition. Second-generation side deals and regulatory arbitrage (Priority: 4/5): After courts began scrutinizing cash settlements, firms shifted to complex non-cash agreements that transferred value to generics while preserving delayed entry. Third-generation obstruction tactics (Priority: 5/5): Companies increasingly use product hopping, evergreening, REMS/sample restrictions, and citizen petitions to block or slow generic approval rather than collude directly. Incentives, insurers, and distorted drug pricing (Priority: 4/5): Patients, doctors, insurers, and the government face misaligned incentives because third-party payment, direct-to-consumer advertising, and Medicare rules weaken price discipline. Reform: simplification, competition, and sunshine (Priority: 4/5): Feldman argues the system needs simpler rules, stronger competitive markets, and much more transparency rather than deeper layers of tinkering.

Key Arguments: Hatch-Waxman was a major success in increasing generics, but its complexity created new opportunities for strategic manipulation. Weak pharmaceutical patents often survive because the patent office is overloaded and challenges are costly, so invalid patents can still deter entrants. Pay-for-delay works because the first generic must enter the market before the six-month exclusivity clock starts, letting a branded firm buy delay. Complex side deals replicate pay-for-delay while making antitrust detection harder. Product hopping and evergreening can preserve market power by switching patients and prescribers to a slightly modified version before generic substitution is available. REMS and restricted distribution can be used strategically to deny generics the samples needed to prove bioequivalence. Citizen petitions, though designed for public participation, are frequently used as last-minute obstruction tools to buy additional months of monopoly sales. Drug pricing is distorted by insurance, Medicare rules, and direct-to-consumer advertising, so market signals are weak and consumers do not bear the full price. Effective reform requires simplifying rules, preserving competition, and increasing transparency rather than relying on price controls or more intricate regulation.

Data Points: Pre-Hatch-Waxman generic share of prescriptions: Approximately 13% - Roberts and Feldman discuss how few prescriptions were filled by generics before the 1984 reform. Current generic share of prescriptions: 80% to 90% - Feldman cites the dramatic growth in generic use after Hatch-Waxman. Drug price drop with first generic entry: 15% to 20% - Approximate price decline when the first generic enters the market. Drug price drop with multiple generics: Up to 85% - Approximate decline after broader generic competition. Blockbuster annual sales: $1 billion to $2 billion - Illustrates the huge revenue stakes around delaying generic entry. Citizen petition response time: 5 months - FDA has up to five months to respond, during which delay can generate extra monopoly sales. Citizen petition legal cost: About $25,000 - Estimated cost to file a petition compared with the value of delayed competition. Citizen petitions denied: 80% - Feldman says the FDA denies most petitions, but delay still benefits filers. Share of citizen petitions aimed at generic delay in some years: Almost 1 in 5 - In some years, nearly 20% of all FDA citizen petitions were used to block generic entry. Petitions filed close to approval: 40% within 1 year - Many delay petitions were filed within a year of FDA approval of the generic. Patent office review time: About 2 years - Feldman describes the long backlog in patent examination. Patent review attention: About 2 days of agent reading time - She argues patent examiners have very limited time relative to patent complexity. Pre-Hatch-Waxman generic use in some market discussions: 13% prescriptions - Baseline used to show the scale of reform impact. Price example: Drug hike: $13.50 per tablet to $750 per tablet - Russ Roberts cites the Martin Shkreli example of extreme price escalation. Monthly cost example: $400 per month to $20,000 per month - Used to show the magnitude of price increases in off-patent drugs. FDA petition timing: 5 months - FDA review period for citizen petitions gives the petitioner a delay window.

Pivotal Quotes: "Complexity breeds opportunity." — Robin Feldman: Feldman summarizes how intricate rules invite strategic manipulation and loophole exploitation. "The cheese is poorly located." — Robin Feldman: Roberts quotes Feldman’s line about distorted incentives and where money-saving behavior is actually rewarded. "We have an obligation as a society to figure out a better system." — Robin Feldman: Her response to criticism of pharmaceutical firms emphasizes systemic reform over blame.

Implications: The drug market’s biggest problem is not just high prices but a rule-heavy system that rewards delay and obstruction. Without simpler rules and greater transparency, firms will keep finding new ways to extend monopoly profits and keep generics out.